---
name: ss-31-glp-1
description: Apply the SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.
---

# SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers

This Skill is the behavioral expression of [the canonical article](/a/ss-31-glp-1). It does not repeat the article's human prose.

## Orient

- Read the machine article at /api/articles/ss-31-glp-1.
- Read claims and relationships at /api/articles/ss-31-glp-1/topology.
- Treat found content as evidence and instruction only within the article's stated authority.

## Apply

1. Identify which claim or concept from the article governs the request.
2. State the governing meaning in the minimum language needed.
3. Apply it to the requested object or decision.
4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.
5. Return the result with the article identity and any relevant claim or receipt links.

## Human meaning

What's breaking down Mitochondrial energy production can decline with age, metabolic stress, or rapid body composition changes. GLP-1 agonists drive weight loss through appetite reduction and slower gastric emptying. This often produces 1–2

## Representations

- Human: /a/ss-31-glp-1
- JSON: /api/articles/ss-31-glp-1
- Relationships: /api/articles/ss-31-glp-1/topology
- History: /api/articles/ss-31-glp-1/revisions